In KOSR-protected CML cells, imatinib still inhibited the BCR-ABL tyrosine kinase, reduced the phosphorylation of STAT, ERK and AKT, down-regulated BCL2, BCLxL, MCL1 and up-regulated BIM. Here, BCL2L11 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.